Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab [3]

Rheumatology

Volumn 41, Issue 10, 2002, Pages 1194-1195

  Roddy, E ^a,c   Courtney, P A ^a   Morris, A ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CENTROMERE ANTIBODY; CLOFAZIMINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METICILLIN; TACROLIMUS;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL ADMISSION; HUMAN; LETTER; LYMPH NODE BIOPSY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SKIN BIOPSY; SKIN ULCER; TREATMENT FAILURE; WOUND HEALING;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED;

EID: 0036796754     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in polymyositis and dermatomyositis. Clin Rheurnatol 2000;19:352-9.
2. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune-globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
3. Transmissible spongiform encephalopathy/new variant Creutzfeldt-Jakob disease - recommendations of the Committee on Safety of Medicines at a meeting held on 30th April 1998.
4. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
5. Maini R, St Clair EW, Bredveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
6. Baeten D, Kruithof E, Van den Bosch F et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy: histological findings in eight patients from an open label pilot study. Arthritis Rheum 2001;44:186-95.
7. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
8. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
9. Hengstman G, van den Hoogen F, van Engelen B, Barrera P, Netea M, van de Putte L. Anti-TNF blockade with infliximab in polymyositis and dermatomyositis. Arthritis Rheum 2000;43:S193.
10. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study. Lancet 2001;357:96-100.
11. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid? A matched cohort study. Br J Rheumatol 1996;35:738-45.